Table 6.
Healthcare resource utilization at index/enrollment (FAS)
| Isavuconazole (n = 510) | Posaconazole (n = 540) | Voriconazole (n = 491) | Multiple/sequenced MAT therapiesa (n = 452) | Total (n = 1993) | |
|---|---|---|---|---|---|
| n | 358 | 411 | 398 | 381 | 1548 |
| Length of initial hospital stay (days)a | |||||
| Median (95% CI) | 23.0 (21.0, 26.0) | 28.0 (26.0, 30.0) | 25.0 (22.0, 27.0) | 27.0 (25.0, 30.0) | 26.0 (25.0, 27.0) |
| In ICU at time of MAT initiation, n (%) | |||||
| Patient in ICU | 131 (36.6) | 56 (13.6) | 128 (32.2) | 99 (26.0) | 414 (26.7) |
| Ventilated at time of MAT initiation, n (%) | |||||
| Patient used ventilator | 80 (22.3) | 23 (5.6) | 68 (17.1) | 58 (15.2) | 229 (14.8) |
| Total time on ventilator (days)b | |||||
| n | 79 | 23 | 68 | 58 | 228 |
| Mean (SD) | 17.5 (39.03) | 15.1 (22.23) | 26.9 (50.73) | 16.5 (23.36) | 19.8 (38.60) |
Almost all patients were treated in an inpatient setting at the time of MAT index/enrollment; only two patients in the voriconazole group were treated in an outpatient setting and are not included in this table. The table contains healthcare resource utilization data corresponding to index MAT (protocol v1.1) or MAT at enrollment (protocol v2.1). Percentages were based on the number of patients in the FAS or n for each parameter. The n for each parameter was the number of patients with inpatient setting of care at index/enrollment with non-missing data for that parameter. Patients were counted only once for the ‘ICU at time of MAT initiation’ and ‘Ventilated at time of MAT initiation’ categories
CI confidence interval, FAS full analysis set, ICU intensive care unit, MAT mold-active triazole, SD standard deviation
aLength of stay was calculated as discharge date − admission date + 1 and was censored at the date of death or study discontinuation
bTotal time on ventilator (days) was calculated as the sum of (ventilator end date − ventilator start date + 1) for all ventilator occurrences